Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Profit After Tax came in at $5.5 billion in Q2 2026, little changed year-over-year from $5.5 billion in Q2 2025, and up 5.71% quarter-over-quarter from $5.2 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Profit After Tax across 18 years of filings, most recently posting $5.5 billion for Q2 2026.
- In Q2 2026, Profit After Tax changed 0.05% year-over-year to $5.5 billion; the TTM figure through Jun 2026 stood at $21.0 billion (down 7.17% YoY), while the FY2025 annual figure was $26.8 billion, up 90.56% from the prior year.
- Profit After Tax came in at $5.5 billion for Q2 2026 at Johnson & Johnson, up from $5.2 billion in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $26.0 billion in Q4 2023 to a low of -$491.0 million in Q2 2023.
- Average Profit After Tax over 5 years is $5.8 billion, with a median of $5.0 billion recorded in 2022.
- Year-over-year, Profit After Tax sank 109.54% in 2023 and soared 762.93% in 2024.
- Over 5 years, Profit After Tax stood at $4.5 billion in 2022, then retreated by 7.31% to $4.1 billion in 2023, then decreased by 16.97% to $3.4 billion in 2024, then jumped by 49.11% to $5.1 billion in 2025, then increased by 8.17% to $5.5 billion in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were $5.5 billion in Q2 2026, $5.2 billion in Q1 2026, and $5.1 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -248.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 438.21 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 149.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 5.53 Bn |
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.13 Bn |
| Oct 1, 2023 | 26.03 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 3.52 Bn |
| Oct 2, 2022 | 4.46 Bn |
| Jul 3, 2022 | 4.81 Bn |
| Apr 3, 2022 | 5.15 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |